Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 50, 2012, Pages 20373-20378

  Godoya, Luiz C ^a   Andersona, Chase T M ^a   Chowdhurya, Rajdeep ^a   Trudela, Laura J ^a   Wogana, Gerald N ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cancer; Caspase 3; Chemoresistance

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; BIOTIN; CASPASE 3; CELL PROTEIN; CHEMICAL COMPOUND; CISPLATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYLHYDROXYLASE 2; PROTEASOME; S NITROSOTHIOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHEMOLUMINESCENCE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR MEMBRANE; MEDIATOR; MELANOMA CELL; NITROSATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; PROTEIN TARGETING; SCAVENGING SYSTEM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOGENS; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; NEOPLASM PROTEINS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITROSATION;

EID: 84870877479     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1218938109     Document Type: Article

References (45)

1. Parker KA, et al. (2010) The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy. J Clin Pathol 63(11):1012-1020.
2. Ko JM, Fisher DE (2011) A new era: melanoma genetics and therapeutics. J Pathol 223(2):241-250.
3. Bowden NA, et al. (2010) Nucleotide excision repair gene expression after cisplatin treatment in melanoma. Cancer Res 70(20):7918-7926.
4. Siddik ZH (2003) Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265-7279. (Pubitemid 37487159)
5. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33(1):9-23. (Pubitemid 46137553)
6. Zheng M, et al. (2007) WP760, a melanoma selective drug. Cancer Chemother Pharmacol 60(5):625-633. (Pubitemid 47247274)
7. Xie K, Huang S (2003) Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic Biol Med 34(8):969-986. (Pubitemid 36398557)
8. Ellerhorst JA, et al. (2006) Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene 25(28):3956-3962. (Pubitemid 43990751)
9. Massi D, et al. (2001) Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. J Pathol 194(2):194-200. (Pubitemid 32519969)
10. Fukumura D, Kashiwagi S, Jain RK (2006) The role of nitric oxide in tumour progression. Nat Rev Cancer 6(7):521-534. (Pubitemid 43980541)
11. Palmieri G, et al. (2009) Main roads to melanoma. J Transl Med 7:86.
12. Salvucci O, Carsana M, Bersani I, Tragni G, Anichini A (2001) Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res 61(1):318-326. (Pubitemid 32095733)
13. Liu L, Stamler JS (1999) NO: an inhibitor of cell death. Cell Death Differ 6(10):937-942. (Pubitemid 29520793)
14. Benhar M, Stamler JS (2005) A central role for S-nitrosylation in apoptosis. Nat Cell Biol 7(7):645-646. (Pubitemid 40975742)
15. Jeannin JF, et al. (2008) Nitric oxide-induced resistance or sensitization to death in tumor cells. Nitric Oxide 19(2):158-163.
16. Brüne B (2003) Nitric oxide: NO apoptosis or turning it ON? Cell Death Differ 10(8):864-869.
17. Foster MW, Hess DT, Stamler JS (2009) Protein S-nitrosylation in health and disease: A current perspective. Trends Mol Med 15(9):391-404.
18. Iyer AK, Azad N, Wang L, Rojanasakul Y (2008) Role of S-nitrosylation in apoptosis resistance and carcinogenesis. Nitric Oxide 19(2):146-151.
19. Ekmekcioglu S, et al. (2000) Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 6(12):4768-4775. (Pubitemid 32110418)
20. Ekmekcioglu S, et al. (2003) Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol Cancer Ther 2(1):9-17.
21. Lechner M, Lirk P, Rieder J (2005) Inducible nitric oxide synthase (iNOS) in tumor biology: The two sides of the same coin. Semin Cancer Biol 15(4):277-289. (Pubitemid 41058773)
22. Tang CH, Grimm EA (2004) Depletion of endogenous nitric oxide enhances cisplatininduced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 279(1):288-298. (Pubitemid 38044827)
23. Sikora AG, et al. (2010) Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16(6):1834-1844.
24. Benhar M, Forrester MT, Hess DT, Stamler JS (2008) Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science 320(5879):1050-1054. (Pubitemid 351929542)
25. Arnér ES, Björnstedt M, Holmgren A (1995) 1-Chloro-2,4-dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase. Loss of thioredoxin disulfide reductase activity is accompanied by a large increase in NADPH oxidase activity. J Biol Chem 270(8):3479-3482.
26. Nordberg J, Zhong L, Holmgren A, Arnér ES (1998) Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue. J Biol Chem 273(18):10835-10842. (Pubitemid 28204917)
27. Clark JS, Faisal A, Baliga R, Nagamine Y, Arany I (2010) Cisplatin induces apoptosis through the ERK-p66shc pathway in renal proximal tubule cells. Cancer Lett 297(2):165-170.
28. Sheridan C, Brumatti G, Elgendy M, Brunet M, Martin SJ (2010) An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. Oncogene 29(49):6428-6441.
29. Mannick JB, et al. (2001) S-Nitrosylation of mitochondrial caspases. J Cell Biol 154(6):1111-1116. (Pubitemid 34286189)
30. Chowdhury R, et al. (2012) Nitric oxide produced endogenously is responsible for hypoxia-induced HIF-1α stabilization in colon carcinoma cells. Chem Res Toxicol 25(10):2194-2202.
31. Lim KH, Ancrile BB, Kashatus DF, Counter CM (2008) Tumour maintenance is mediated by eNOS. Nature 452(7187):646-649. (Pubitemid 351483359)
32. Ekmekcioglu S, et al. (2006) Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 119(4):861-866. (Pubitemid 44051450)
33. Li F, et al. (2007) Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 26(1):63-74. (Pubitemid 46550936)
34. Fitzpatrick B, Mehibel M, Cowen RL, Stratford IJ (2008) iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 19(2):217-224.
35. Switzer CH, et al. (2012) Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer. Breast Cancer Res 14(5):R125.
36. Subramaniam S, Unsicker K (2010) ERK and cell death: ERK1/2 in neuronal death. FEBS J 277(1):22-29.
37. Jeffers JR, et al. (2003) Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4(4):321-328. (Pubitemid 37329796)
38. Rohwer N, et al. (2010) Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS ONE 5(8):e12038.
39. Tsunetoh S, et al. (2010) Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Cancer Biol Ther 10(11):1137-1146.
40. Jayaraman P, et al. (2012) Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol 188(11):5365-5376.
41. Forrester MT, et al. (2009) Thioredoxin-interacting protein (Txnip) is a feedback regulator of S-nitrosylation. J Biol Chem 284(52):36160-36166.
42. Jensen MS, Nyborg NC, Thomsen ES (2000) Various nitric oxide donors protect chick embryonic neurons from cyanide-induced apoptosis. Toxicol Sci 58(1):127-134.
43. Forrester MT, Foster MW, Benhar M, Stamler JS (2009) Detection of protein S-nitrosylation with the biotin-switch technique. Free Radic Biol Med 46(2):119-126.
44. Pfeiffer S, et al. (1997) Interference of carboxy-PTIO with nitric oxide- and perox-ynitrite- mediated reactions. Free Radic Biol Med 22(5):787-794. (Pubitemid 27058341)
45. Feelisch M, et al. (2002) Concomitant S-, N-, and heme-nitros(yl)ation in biological tissues and fluids: Implications for the fate of NO in vivo. FASEB J 16(13):1775-1785. (Pubitemid 35340358)